http://biasco.ch/wiki/index.php?action=history&feed=atom&title=Glivec%3AFonti Glivec:Fonti - Cronologia 2026-05-15T07:03:22Z Cronologia della pagina su questo sito MediaWiki 1.26.2 http://biasco.ch/wiki/index.php?title=Glivec:Fonti&diff=1035&oldid=prev Christian il 19:37, 1 set 2008 2008-09-01T19:37:51Z <p></p> <table class='diff diff-contentalign-left'> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr style='vertical-align: top;' lang='it'> <td colspan='2' style="background-color: white; color:black; text-align: center;">← Versione meno recente</td> <td colspan='2' style="background-color: white; color:black; text-align: center;">Versione delle 19:37, 1 set 2008</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l109" >Riga 109:</td> <td colspan="2" class="diff-lineno">Riga 109:</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>Intervista a Annick Hamel, département des Opérations di MSF</div></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>Intervista a Annick Hamel, département des Opérations di MSF</div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://dailymotion.alice.it/relevance/search/novartis/video/x12m3x_msf-vs-novartis_news Video MSF vs Novartis - Novartis, MSF, Droitsauxsoins, Pétition, Médicaments]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://www.greenreport.it/contenuti/leggi.php?id_cont=10661 greenreport - quotidiano ambientale]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://www.thehindubusinessline.com/2007/11/14/stories/2007111452110300.htm The Hindu Business Line : 2-member Bench can look into Novartisâ⊘⊘ Glivec case, says HC]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://www.galileonet.it/primo-piano/8198/trial-clinico-fai-da-te Galileo :: Giornale di scienza e problemi globali » Trial clinico fai da te]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://www.altravoce.net/2007/08/14/farmaci.html l'altra voce :: dopo la sentenza in India che ha respinto il ricorso del gruppo svizzero Novartis]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://cienciaylejos.blogspot.com/2007/04/un-medicamento-contra-el-cncer-ilegal.html Ciencia y Lejos]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://www.essentialdrugs.org/edrug/archive/200402/msg00046.php Essentialdrugs.org]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://www.drugdelivery.ca/s46875-s-GLIVEC.aspx GLIVEC, Buy GLIVEC 100MG GENERIC Online]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://www.hinduonnet.com/fline/fl2208/stories/20050422002003000.htm The Glivec case]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://www.corpwatch.org/article.php?id=14631 CorpWatch : INDIA: Novartis Patents Case Far From Dead]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://www.careinternational.org.uk/Campaign%20Video+9596.twl CARE International UK : Novartis : Campaign Video]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://www.fightglobalaids.org/resources/universalaccess.php Student Global AIDS Campaign]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://video.google.it/videoplay?docid=8762027573633056305&amp;q=glivec&amp;total=5&amp;start=0&amp;num=10&amp;so=0&amp;type=search&amp;plindex=2 Novartis pone en peligro las vidas de millones de personas]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://http://video.google.it/videoplay?docid=-6257096970603264622&amp;q=patents+aids&amp;total=35&amp;start=0&amp;num=10&amp;so=0&amp;type=search&amp;plindex=1 Novartis, Stop It (AIDS Patent)]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://www.lawstudent.in/bcgliveccase.htm The Glivec case]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://http://www.oxfamamerica.org/whatwedo/campaigns/make_trade_fair/news_publications/qna_novartis Oxfam America: Questions and Answers on Novartis and the Glivec Patent Case in India]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://novartisboycott.org/index.php?tag=novartis Boycott Novartis]</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* [http://www.novartis.com/newsroom/india-glivec-patent-case/index.shtml Information Center â⊘⊘ India Glivec patent case]</ins></div></td></tr> </table> Christian http://biasco.ch/wiki/index.php?title=Glivec:Fonti&diff=771&oldid=prev Deneb: /* Documenti di associazioni */ 2008-07-21T17:42:48Z <p>‎<span dir="auto"><span class="autocomment">Documenti di associazioni</span></span></p> <table class='diff diff-contentalign-left'> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr style='vertical-align: top;' lang='it'> <td colspan='2' style="background-color: white; color:black; text-align: center;">← Versione meno recente</td> <td colspan='2' style="background-color: white; color:black; text-align: center;">Versione delle 17:42, 21 lug 2008</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l72" >Riga 72:</td> <td colspan="2" class="diff-lineno">Riga 72:</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>* Care International (non datato), &quot;Novartis loses: a victory for public health&quot;</div></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>* Care International (non datato), &quot;Novartis loses: a victory for public health&quot;</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>** CARE071101.pdf</div></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>** CARE071101.pdf</div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* Claudio Santi, 8 Giugno 2004, &quot;I diritti umani ed il commercio dei farmaci&quot;</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">** http://www.infarmazone.org/Documenti_libreria/commercio%20dei%20farmaci.pdf</ins></div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>==Altro==</div></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>==Altro==</div></td></tr> </table> Deneb http://biasco.ch/wiki/index.php?title=Glivec:Fonti&diff=165&oldid=prev Christian: ha spostato Glivec/Fonti a Glivec:Fonti 2008-05-03T00:09:11Z <p>ha spostato <a href="/wiki/index.php?title=Glivec/Fonti&amp;action=edit&amp;redlink=1" class="new" title="Glivec/Fonti (la pagina non esiste)">Glivec/Fonti</a> a <a href="/wiki/index.php?title=Glivec:Fonti" title="Glivec:Fonti">Glivec:Fonti</a></p> <table class='diff diff-contentalign-left'> <tr style='vertical-align: top;' lang='it'> <td colspan='1' style="background-color: white; color:black; text-align: center;">← Versione meno recente</td> <td colspan='1' style="background-color: white; color:black; text-align: center;">Versione delle 00:09, 3 mag 2008</td> </tr><tr><td colspan='2' style='text-align: center;' lang='it'><div class="mw-diff-empty">(Nessuna differenza)</div> </td></tr></table> Christian http://biasco.ch/wiki/index.php?title=Glivec:Fonti&diff=162&oldid=prev Christian: ha spostato Glivec:Fonti a Glivec/Fonti 2008-05-03T00:00:06Z <p>ha spostato <a href="/wiki/index.php?title=Glivec:Fonti" title="Glivec:Fonti">Glivec:Fonti</a> a <a href="/wiki/index.php?title=Glivec/Fonti&amp;action=edit&amp;redlink=1" class="new" title="Glivec/Fonti (la pagina non esiste)">Glivec/Fonti</a></p> <table class='diff diff-contentalign-left'> <tr style='vertical-align: top;' lang='it'> <td colspan='1' style="background-color: white; color:black; text-align: center;">← Versione meno recente</td> <td colspan='1' style="background-color: white; color:black; text-align: center;">Versione delle 00:00, 3 mag 2008</td> </tr><tr><td colspan='2' style='text-align: center;' lang='it'><div class="mw-diff-empty">(Nessuna differenza)</div> </td></tr></table> Christian http://biasco.ch/wiki/index.php?title=Glivec:Fonti&diff=109&oldid=prev Christian: /* Intellectual Property Watch (http://www.ip**watch.org/) */ 2008-05-02T01:17:00Z <p>‎<span dir="auto"><span class="autocomment">Intellectual Property Watch (http://www.ip**watch.org/)</span></span></p> <table class='diff diff-contentalign-left'> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr style='vertical-align: top;' lang='it'> <td colspan='2' style="background-color: white; color:black; text-align: center;">← Versione meno recente</td> <td colspan='2' style="background-color: white; color:black; text-align: center;">Versione delle 01:17, 2 mag 2008</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l74" >Riga 74:</td> <td colspan="2" class="diff-lineno">Riga 74:</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>==Altro==</div></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>==Altro==</div></td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>===Intellectual Property Watch <del class="diffchange diffchange-inline">(</del>http://www.ip**watch.org/<del class="diffchange diffchange-inline">)===</del></div></td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>===Intellectual Property Watch<ins class="diffchange diffchange-inline">===</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>http://www.ip**watch.org/</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>31/01/2008: Thailand Avoids Compulsory Licence On Cancer Drug; 3 More Drugs Undecided</div></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>31/01/2008: Thailand Avoids Compulsory Licence On Cancer Drug; 3 More Drugs Undecided</div></td></tr> </table> Christian http://biasco.ch/wiki/index.php?title=Glivec:Fonti&diff=108&oldid=prev Christian: Nuova pagina: ==Documenti Novartis== * [Videoblog.GlivecFonte0000Novartis1]: Cronologia del Glivec in India (2007) * [Videoblog.GlivecFonte0000Novartis2]: "Il caso Glivec in India, tra realtà e ... 2008-05-02T01:16:28Z <p>Nuova pagina: ==Documenti Novartis== * [Videoblog.GlivecFonte0000Novartis1]: Cronologia del Glivec in India (2007) * [Videoblog.GlivecFonte0000Novartis2]: &quot;Il caso Glivec in India, tra realtà e ...</p> <p><b>Nuova pagina</b></p><div>==Documenti Novartis==<br /> * [Videoblog.GlivecFonte0000Novartis1]: Cronologia del Glivec in India (2007)<br /> <br /> * [Videoblog.GlivecFonte0000Novartis2]: &quot;Il caso Glivec in India, tra realtà e ‘fiction’&quot; (2007?)<br /> <br /> * Novartis (non datato), &quot;Questions &amp; answers&quot;<br /> ** NovartisXXfaq.pdf (C)<br /> <br /> * Novartis (non datato), &quot;Domande e risposte&quot;<br /> ** Novartis07DomandeErisposte.pdf (C)<br /> <br /> * Novartis (non datato), &quot;Improving Indian patent law benefits patients and societies&quot; aka &quot;Migliorare la legge indiana sui brevetti va a vantaggio dei pazienti e della collettività&quot;<br /> ** NovartisXXImprovingIndianpatentlaw.pdf (C)<br /> ** Novartis07Posizione.pdf (C)<br /> <br /> * Novartis (non datato, pres. dopo il 6 agosto 2007), &quot;La sentenza del tribunale indiano scoraggerà gli investimenti in innovazione necessari per assicurare farmaci migliori ai pazienti&quot;<br /> ** Novartis070806comunicatostampa.pdf (C)<br /> <br /> * Novartis, &quot;An open letter from Novartis regarding the Glivec legal challenge in India: Why Novartis thinks improving patent law will benefit patients and society&quot;, 29 January 2007<br /> ** Novartis070129openletter.pdf (C)<br /> <br /> * Novartis (non datato), &quot;Novartis concerned Indian court ruling will discourage investments in innovation needed to bring better medicines to patients&quot;<br /> ** Novartis07NovartisconcernedIndiancourt.pdf (C)<br /> <br /> * Novartis (non datato), &quot;Patents explained&quot;<br /> ** NovartisXXpatent**explained.pdf<br /> <br /> * Novartis (non datato), &quot;Glossary of Key Agreements and Terms&quot;<br /> ** NovartisXXkey**terms.pdf (C)<br /> <br /> * Novartis, &quot;To the signatories of the CARE email campaign&quot;, August 2007<br /> ** Novartis070809answerCARE.pdf<br /> <br /> * Novartis (non datato), &quot;Addressing innovation dilemmas in emerging markets: Glivec case advances debate in India&quot;<br /> ** NovartisXXDilemmasinemerging.pdf (C)<br /> <br /> ==Articoli di giornale italiani==<br /> <br /> * Lettere al Corriere della Sera, 20 febbraio <br /> ** 7 marzo 2007, in risposta ad un articolo o lettera di Beppe Severgnini. Fra le 7 lettere trovate, 3 sono della Direttore Comunicazione Novartis Italia, Angela Bianchi.<br /> <br /> ==Articoli di giornale stranieri==<br /> <br /> * Feroz Ali K, &quot;Novartis: do Indian patent laws stifle research?&quot;, The Hindu, 9 Aug 2007.<br /> ** http://www.hindu.com/seta/2007/08/09/stories/2007080950161500.htm (C)<br /> <br /> ==Riviste scientifiche==<br /> * Mueller, Janice M., &quot;Taking TRIPS to India ** Novartis, Patent Law, and Access to Medicines&quot;, New England Journal of Medicine, 8 Feb 2008, p. 541. (C)<br /> <br /> * Stiglitz, Joseph E, &quot;Scrooge and intellectual property rights&quot;, Br Med J, 23**30. Dec 2006, 1279**80.<br /> ** BMJ061223Stiglitz.pdf<br /> ** risposta di Christian Engström, Vice chairman, The Pirate Party (Sweden), &quot;The Swedish Pirate Party agrees&quot;, 31 Dez 2006.<br /> *** http://www.bmj.com/cgi/eletters/333/7582/1279#152401<br /> <br /> ==Documenti di associazioni==<br /> <br /> * Berne Declaration, letter to Novartis, 10 Oct 2006<br /> ** BD061010Reinhard<br /> <br /> * Oxfam, &quot;Des brevets contre des patients. Cinq ans après la Déclaration de Doha&quot;, November 2006<br /> ** http://www.oxfam.org/fr/policy/briefingpapers/bp95_patentsvspatients_061114 (C)<br /> <br /> * Oxfam (Hobbis, Jeremy), letter to Novartis, 12 feb 2007<br /> ** Oxfam070212Hobbs.pdf<br /> <br /> * Guidieri, Elena, &quot;Multinazionale Farmaceutica denuncia India&quot;, Misericordia Ponte di Mezzo, 2007?, Firenze.<br /> ** http://www.misericordiapontedimezzo.org/index.php?option=com_content&amp;task=view&amp;id=68&amp;Itemid=157 (C)<br /> <br /> * Care International, letter to Novartis, 19 Jun 2007<br /> ** CARE070619Stanojevich<br /> <br /> * Care International (non datato), &quot;Novartis loses: a victory for public health&quot;<br /> ** CARE071101.pdf<br /> <br /> ==Altro==<br /> ===Intellectual Property Watch (http://www.ip**watch.org/)===<br /> <br /> 31/01/2008: Thailand Avoids Compulsory Licence On Cancer Drug; 3 More Drugs Undecided<br /> <br /> 29/01/2008: Cuestionan la constitucionalidad de las patentes brasileñas de concesión retroactiva<br /> <br /> 29/01/2008: La justice s’interroge sur la constitutionnalité du système brésilien de pipeline<br /> <br /> 22/01/2008: Challenge Raised To Constitutionality Of Brazilian Pipeline Patents<br /> <br /> 01/12/2007: EU Acceptance Of TRIPS Health Amendment Adds 28 Members<br /> <br /> 05/11/2007: Thailand: Latest Talks With Patent Owners of Cancer Drugs Show Positive Results<br /> <br /> 02/11/2007: Thailand: 20 More Drugs In Pipeline For Possible Compulsory Licences<br /> <br /> 07/08/2007: Rejected Novartis Cases Leave India’s TRIPS Compliance Unchallenged<br /> <br /> 18/06/2007: Novartis Case Against India’s Patent Law Resumes This Week<br /> <br /> 04/04/2007: Ruling On Novartis Challenge To WTO Rules In India Could Come Early (C)<br /> <br /> 19/10/2006: Novartis Persists With Challenge To Indian Patent Law Despite Adversity<br /> <br /> ==Altre fonti (video, audio, foto)==<br /> <br /> Lo spot della Campagna di MSF &quot;Prima la gente poi i brevetti&quot;<br /> <br /> http://www.msf.fr/site/site.nsf/pages/dossiernovartisspot<br /> <br /> Intervista a Annick Hamel, département des Opérations di MSF</div> Christian